Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Moxonidine→

Moxonidine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
75438-57-2
Molecular formula
C9H12ClN5O
Molecular weight
241.68 g/mol
Drug class
Centrally acting antihypertensiveselective imidazoline I1-receptor agonist
Mechanism of action
Binds selectively to I1-imidazoline receptors in the rostral ventrolateral medulla, reducing central sympathetic outflow. This lowers peripheral vascular resistance and arterial blood pressure; affinity for central alpha-2-adrenoceptors is relatively weak.
Indications / reported uses
  • Treatment of essential hypertension, according to the applicable product label.

Sources: https://www.medicines.org.uk/emc/product/4138/smpc · https://www.medicines.org.uk/emc/product/4139/smpc

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Moxonidine Environmental Risk Assessment (ERA) (the Moxonidine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.